New combo aims to rev up immune system against lung cancer
NCT ID NCT05493566
First seen Feb 17, 2026 · Last updated Jun 23, 2026 · Updated 12 times
Summary
This early-phase trial tests whether adding low-dose interleukin-2 (IL-2) to the immunotherapy drug pembrolizumab (Keytruda) can better activate the immune system against stage IV non-small cell lung cancer. The study will enroll 15 people who have not had prior treatment for their advanced cancer. Researchers will measure changes in immune cells and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Low-dose interleukin-2 (IL-2) plus pembrolizumab (Keytruda)
What this could lead to
If it works, this could point toward a more effective immune-based treatment for advanced lung cancer.
What could go wrong
This is a very early (Phase 1) trial with only 15 people. It is designed mainly to check immune response, not yet to prove the treatment works. Side effects from the drug combination are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.